Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GRK6 | P43250 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | XBP1 | P17861 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25399863 | 0.94 | KMT2A (0.46) | SMN1; SMN2KMT2APOLBNR2F2MAPK1 | |
| SCHEMBL9681221 | 0.94 | KMT2A (0.44) | SMN1; SMN2KMT2APOLBNR2F2MAPK1 | |
| SCHEMBL16344633 | 0.93 | KMT2A (0.48) | SMN1; SMN2KMT2APOLBNR2F2MAPK1 | |
| SCHEMBL18394940 | 0.90 | KCNJ6 (0.44) | SMN1; SMN2KMT2APOLBKDM4EMAPT | |
| SCHEMBL24880478 | 0.90 | PLAT (0.44) | SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL24880957 | 0.90 | KMT2A (0.42) | SMN1; SMN2KMT2APOLBALDH1A1FAAH | |
| Hydrochloric Acid SCHEMBL27216607 | 0.89 | PLAT (0.43) | SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL20944278 | 0.87 | KMT2A (0.40) | SMN1; SMN2KMT2APOLBMAPK1NPSR1 | |
| SCHEMBL23213997 | 0.85 | KMT2A (0.39) | SMN1; SMN2KMT2APOLBMAPK1MAPT | |
| SCHEMBL27256369 | 0.84 | SMN1; SMN2 (0.45) | SMN1; SMN2KMT2APOLBMAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025245472-A1 | COMPOUNDS AND RELATED METHODS USEFUL FOR DEGRADATION OF CYCLIN K AND INHIBITION OF CYCLIN DEPENDENT KINASES | REMIX THERAPEUTICS INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-11492358-B1 | Macrocyclic indole derivatives | THE BROAD INSTITUTE, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| EP-3458459-B1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER AG (DE) | 2022-04-27 | — | — | EP | disclosed |
| EP-3458459-B1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER AG (DE) | 2022-04-27 | — | — | EP | disclosed |
| CN-109715632-B | Macrocyclic indole derivatives | 拜尔公开股份有限公司 | 2021-10-26 | — | — | CN | disclosed |
| US-10981932-B2 | Macrocyclic indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-20 | — | — | US | disclosed |
| US-10981932-B2 | Macrocyclic indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-20 | — | — | US | disclosed |
| US-20200087322-A1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-03-19 | — | — | US | disclosed |
| EP-3458459-A1 | MACROCYCLIC INDOLE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017198341-A1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2017-11-23 | — | — | WO | disclosed |
| US-20160095843-A1 | PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2016-04-07 | — | — | US | disclosed |
| US-20160095843-A1 | PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2016-04-07 | — | — | US | disclosed |
| US-20160095843-A1 | PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2016-04-07 | — | — | US | disclosed |
| US-8975417-B2 | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2015-03-10 | — | — | US | disclosed |
| US-8975417-B2 | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2015-03-10 | — | — | US | disclosed |
| US-8975417-B2 | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2015-03-10 | — | — | US | disclosed |
| WO-2014191896-A1 | PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2014-12-04 | — | — | WO | disclosed |
| US-20140349990-A1 | Pyrazolopyrrolidine Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2014-11-27 | — | — | US | disclosed |
| US-20140349990-A1 | Pyrazolopyrrolidine Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2014-11-27 | — | — | US | disclosed |
| US-20140349990-A1 | Pyrazolopyrrolidine Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160095843-A1 | PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | PKD1, PKD2, REN | SMN1; SMN2 1147/4885KMT2A 3613/4885POLB 2322/4885 |
| US-20140349990-A1 | Pyrazolopyrrolidine Derivatives and their Use in the Treatment of Disease | PKD1, PKD2, REN | SMN1; SMN2 1225/4885KMT2A 3658/4885POLB 2315/4885 |
| US-11492358-B1 | Macrocyclic indole derivatives | CCND2, CCNT2, IDO1 | SMN1; SMN2 4099/4885KMT2A 930/4885POLB 2024/4885 |
| US-10981932-B2 | Macrocyclic indole derivatives | CCND2, IDO1, CCNT2 | SMN1; SMN2 4139/4885KMT2A 772/4885POLB 2267/4885 |
| US-20200087322-A1 | MACROCYCLIC INDOLE DERIVATIVES | CCND2, CCNA1, CCNT2 | SMN1; SMN2 4202/4885KMT2A 897/4885POLB 2027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.